JNJ-40346527 was identified in a medicinal-chemistry lead optimization study to develop oral, selective CSF1R kinase inhibitors. JNJ-40346527 is compound I-S in patent US20140045789 [2]. PubChem CID 25230468 is a tautomer which is also claimed in the patent. Clinical development of JNJ-40346527 was terminated in 2014 due to a lack of efficacy.